

Product Name: Ki 20227

Catalog No.: 4481


Batch No.: 7

CAS Number: 623142-96-1

IUPAC Name: *N*-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-*N'*-[1-(2-thiazolyl)ethyl]urea

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₄H₂₄N₄O₅S
Batch Molecular Weight: 480.54
Physical Appearance: White solid
Solubility: DMSO to 100 mM
Storage: Store at +4°C
Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 100.0% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	59.99	5.03	11.66
Found	59.84	4.99	11.53

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: Ki 20227

Catalog No.: 4481

Batch No.: 7

CAS Number: 623142-96-1

IUPAC Name: *N*-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-*N'*-[1-(2-thiazolyl)ethyl]urea

Description:

Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC₅₀ values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₄H₂₄N₄O₅S

Batch Molecular Weight: 480.54

Physical Appearance: White solid

Minimum Purity: ≥97%

Batch Molecular Structure:



Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. *J.Exp.Med.* **206** 1089. PMID: 19398755.

Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. *Eur.J.Immunol.* **38** 283. PMID: 18085662.

Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. *Mol.Cancer Ther.* **5** 2634. PMID: 17121910.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel:+1 612 379 2956